Inclusion Criteria:

• signed written informed consent
• male or female
• age ≥ 18 years
• patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
• SOC clinical follow-up at the cardiology department in CHUV.

Exclusion Criteria:

The presence of any one of the following exclusion criteria will lead to exclusion of the participant:

• absence of a signed written informed consent

• patients aged < 18 years

• claustrophobia

• myocardial ischemia in non-invasive perfusion test or coronarography in group II and III

• clinically unstable cardiovascular conditions, including:

  • clinically unstable brady-tachyarrhythmia
  • severe and symptomatic hypo- or hypertension with documented systolic blood pressure < 90 mmHg or ≥220 mmHg respectively
  • cardiogenic shock.

• women who are pregnant or breast feeding

• intention to become pregnant during the course of the study in group II

• previous enrolment into the current study

• moderate to severe renal insufficiency (GFR < 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III

• enrollment of the investigator, his/her family members, employees and other dependent persons

• history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment

• insufficient knowledge of project language, inability to give consent or to follow procedures

• the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings